Phase 3 Lung Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 years or older.
- People whose overall health and ability to carry out daily activities falls within a certain range, as rated by a standard medical scale called the ECOG scale (scores 0–2, meaning fully active to capable of some self-care).
- People who have a confirmed diagnosis of non-small cell lung cancer (NSCLC), proven through a tissue or cell sample.
- People with between 1 and 5 sites of cancer spread (metastases) in the body, not counting the original lung tumour or nearby lymph nodes, with no more than 3 metastatic spots in any single organ.
- People who have completed a standard course of systemic treatment (such as chemotherapy or immunotherapy) lasting 4 to 6 cycles, and whose disease has not gotten worse during that time.
- People whose primary (original) lung tumour is considered suitable for definitive (aimed at full treatment) therapy.
- People whose metastatic spots are visible on scans and are considered suitable for high-dose, targeted radiation treatment.
- People who have already received ablative radiation, surgery, or radiofrequency ablation (RFA) for metastatic sites, as long as the total number of metastatic sites (including those already treated) is 5 or fewer at the time of joining the study.
- People who have received lower-dose (palliative) radiation or RFA for painful bone metastases, as long as that treated area appears stable on imaging — or, if not stable, a treating doctor considers further high-dose radiation to be possible.
- People who have had surgery for bone metastases followed by palliative radiation, as long as the treated site appears stable on imaging and the total number of metastatic sites is fewer than 5 at the time of joining.
- People with blood counts measured within 15 days before joining the study that meet minimum levels: white blood cell count (neutrophils) at least 500 cells/mm³, platelets at least 50,000 cells/mm³, and haemoglobin at least 8.0 g/dL (including if achieved through a blood transfusion or similar support).
- Women who could become pregnant must have a negative pregnancy test (blood or urine) within 14 days before joining the study.
- People who are willing to provide written informed consent and are able to attend the required follow-up appointments.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer has continued to grow or spread during their initial systemic treatment.
- People whose lung cancer is driven by specific gene mutations (oncogene driver mutations) (confirm with trial site for which mutations apply).
- People with more than 5 sites of cancer spread in the body.
- People with any individual metastatic tumour larger than 5 cm in size.
- People with more than 3 metastatic spots within a single organ.
- People whose primary lung tumour is not considered suitable for definitive radiation treatment.
- People whose metastatic sites are not considered suitable for high-dose ablative radiation.
- People with cancer that has spread to the lining of the abdomen (peritoneal disease).
- People with cancer cells found in the fluid around the lungs (malignant pleural effusion).
- People with cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease).
- People with cancer that has spread to the brain stem.
- People with evidence of spinal cord compression, or metastases located within 2 mm of the spinal cord as seen on an MRI scan.
- People with serious, unstable heart conditions — including unstable chest pain or heart failure requiring hospitalisation in the past 6 months, or a full-thickness heart attack in the past 6 months.
- People with a severe lung condition (such as COPD) that has recently required hospitalisation or that would prevent participation in the study.
- People who have previously received radiation treatment to the chest area.
- People who have had another cancer diagnosed within the last 3 years.
- People who are currently pregnant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If this is close to home
This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.
- Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
- Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
- Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
- Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
- Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14
Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.
Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Principal Investigator: Dr. Anil Tibdewal, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India
Phone: +91-22-24177000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Overall survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.